Next Article in Journal
Local Preirradiation of Infarcted Cardiac Tissue Substantially Enhances Cell Engraftment
Next Article in Special Issue
Immunostimulatory Potential of Extracellular Vesicles Isolated from an Edible Plant, Petasites japonicus, via the Induction of Murine Dendritic Cell Maturation
Previous Article in Journal
circRNA-Mediated Inhibin–Activin Balance Regulation in Ovarian Granulosa Cell Apoptosis and Follicular Atresia
Article

Enhancement of Immune Checkpoint Inhibitor-Mediated Anti-Cancer Immunity by Intranasal Treatment of Ecklonia cava Fucoidan against Metastatic Lung Cancer

1
Shanghai Public Health Clinical Center, Shanghai Medical College, Fudan University, Shanghai 201508, China
2
Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Korea
3
Research Institute of Cell Culture, Yeungnam University, Gyeongsan 38541, Korea
4
Department of Chemistry, Pukyong National University, Busan 48513, Korea
5
ASAN Medical Center, Department of Biomedical Sciences, University of Ulsan College of Medicine, Seoul 05505, Korea
*
Authors to whom correspondence should be addressed.
These authors contributed equally to the work.
Academic Editor: Udo S. Gaipl
Int. J. Mol. Sci. 2021, 22(17), 9125; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22179125
Received: 6 July 2021 / Revised: 11 August 2021 / Accepted: 20 August 2021 / Published: 24 August 2021
(This article belongs to the Special Issue Dendritic Cell and Cancer Therapy)
Although fucoidan, a well-studied seaweed-extracted polysaccharide, has shown immune stimulatory effects that elicit anticancer immunity, mucosal adjuvant effects via intranasal administration have not been studied. In this study, the effect of Ecklonia cava-extracted fucoidan (ECF) on the induction of anti-cancer immunity in the lung was examined by intranasal administration. In C57BL/6 and BALB/c mice, intranasal administration of ECF promoted the activation of dendritic cells (DCs), natural killer (NK) cells, and T cells in the mediastinal lymph node (mLN). The ECF-induced NK and T cell activation was mediated by DCs. In addition, intranasal injection with ECF enhanced the anti-PD-L1 antibody-mediated anti-cancer activities against B16 melanoma and CT-26 carcinoma tumor growth in the lungs, which were required cytotoxic T lymphocytes and NK cells. Thus, these data demonstrated that ECF functioned as a mucosal adjuvant that enhanced the immunotherapeutic effect of immune checkpoint inhibitors against metastatic lung cancer. View Full-Text
Keywords: Ecklonia cava fucoidan; mucosal adjuvant; anti-PD-L1 antibody; immunotherapy; anti-cancer Ecklonia cava fucoidan; mucosal adjuvant; anti-PD-L1 antibody; immunotherapy; anti-cancer
Show Figures

Figure 1

MDPI and ACS Style

Zhang, W.; Hwang, J.; Yadav, D.; An, E.-K.; Kwak, M.; Lee, P.C.-W.; Jin, J.-O. Enhancement of Immune Checkpoint Inhibitor-Mediated Anti-Cancer Immunity by Intranasal Treatment of Ecklonia cava Fucoidan against Metastatic Lung Cancer. Int. J. Mol. Sci. 2021, 22, 9125. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22179125

AMA Style

Zhang W, Hwang J, Yadav D, An E-K, Kwak M, Lee PC-W, Jin J-O. Enhancement of Immune Checkpoint Inhibitor-Mediated Anti-Cancer Immunity by Intranasal Treatment of Ecklonia cava Fucoidan against Metastatic Lung Cancer. International Journal of Molecular Sciences. 2021; 22(17):9125. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22179125

Chicago/Turabian Style

Zhang, Wei, Juyoung Hwang, Dhananjay Yadav, Eun-Koung An, Minseok Kwak, Peter C.-W. Lee, and Jun-O Jin. 2021. "Enhancement of Immune Checkpoint Inhibitor-Mediated Anti-Cancer Immunity by Intranasal Treatment of Ecklonia cava Fucoidan against Metastatic Lung Cancer" International Journal of Molecular Sciences 22, no. 17: 9125. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22179125

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop